PUBLICATION
Evaluation of in vitro and in vivo personalized cancer treatment assays for oral squamous cell carcinoma
- Authors
- Wahbi, W., Korelin, K., Sieviläinen, M., Karihtala, P., Wilkman, T., Tarkkanen, J., Salo, T., Al-Samadi, A.
- ID
- ZDB-PUB-230427-52
- Date
- 2023
- Source
- Translational oncology 33: 101677101677 (Journal)
- Registered Authors
- Keywords
- Microfluidic chip, Myogel, Oral cancer, Personalized medicine, Zebrafish
- MeSH Terms
- none
- PubMed
- 37099957 Full text @ Transl Oncol
Citation
Wahbi, W., Korelin, K., Sieviläinen, M., Karihtala, P., Wilkman, T., Tarkkanen, J., Salo, T., Al-Samadi, A. (2023) Evaluation of in vitro and in vivo personalized cancer treatment assays for oral squamous cell carcinoma. Translational oncology. 33:101677101677.
Abstract
Background Oral squamous cell carcinoma (OSCC) is a common cancer with a high heterogeneity and few approved treatments. OSCC is one of the least explored areas for precision oncology. In this study, we aimed to test the reliability of our three established rapid cancer systemic treatment-testing assays: human tumour-derived matrix (Myogel)-coated well-plates, zebrafish xenografts, and 3D microfluidic chips.
Methods Chemo-, radio- and targeted-therapy testing in Myogel-coated wells and zebrafish xenografts was conducted nine times using five samples; two primary and three metastatic lymph node samples from three OSCC patients. Peripheral blood mononuclear cells (PBMNCs) were isolated from the patients' blood. The response of the tumour cells to radio-, chemo-, and targeted therapy was tested using Myogel-coated wells and zebrafish larvae xenografts. The tumour cells' response to immunotherapy was tested using 3D microfluidic chips. The cells' sensitivity to the treatments was compared with the patients' clinical response. Primary and metastatic lymph node tissue-derived DNA samples from two patients underwent whole exome sequencing to compare the mutational profiles of the samples.
Results Test results were in line with patients' responses in 7/9 (77%) zebrafish xenograft assays and 5/9 (55%) Myogel-coated wells assays. Immunotherapy testing was done using one metastatic patient sample which matched the patients' response. Differences in responses to treatments between primary and metastatic samples of the same patient were detected in 50% of the zebrafish larvae assays.
Conclusions Our results show the potential of using personalized cancer treatment testing assays - specifically zebrafish xenografts that revealed promising results - in OSCC patient samples.
Genes / Markers
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Orthology
Engineered Foreign Genes
Mapping